Article
Dr. Jack Cush reviews the news, journal reports, survey results and "Back Talk" questions from Rheums.
All News
Article
The FDA has approved Gilead Sciences Inc’s antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.
Article
A number of recently published clinical trials are further defining the efficacy and outcomes of tocilizumab or remdesivir in treating SARs-CoV-2 infection.
Remdesivir
Article
Prospective observational findings from the CORRONA registry of rheumatoid arthritis (RA) patients compared clinical outcomes between initial aggressive therapy using either a tumour necrosis factor inhibitor (TNFi) or a non-TNFi (biological disease-modifying antirheumatic drugs (bDMARDs) and tar
Article
The U.S. Food and Drug Administration announced today in a Drug Safety Communication that it is requiring labeling changes for nonsteroidal anti-inflammatory drugs (NSAIDs).
Article
Dr. Jack Cush sings the news and journal reports from the past week on RheumNow.com.
Article
NEJM reports the results of the SELECT-Choice trial, a head to head study of upadacitinib (UPA) and abatacept (ABA) in biologic refractory rheumatoid arthritis (RA); 12 weeks results showed UPA was significantly more clinically effective than ABA using a DAS28-CRP remission, but ABA had fewer safety signals and serious adverse events.
Article
Cancer patients treated with immune checkpoint inhibitors (ICI) who develop severe arthritis may be at risk for progression of the malignancy, a single-center study suggested.
Article
Mease and colleagues have reviewed the tofacitinib drug development and clinical trial data, finding the risk of venous (VTE) and arterial thromboembolism (ATE) to be low and augmented in patients with baseline cardiovascular abd VTE risk factors and those taking higher doses of tofacitinib (10 m
Article
A large RA cohort study from the Swedish Rheumatology Quality Register shows a higher risk of venous thromboembolism (VTE) in rheumatoid arthritis (RA) and that risk is linked to RA disease activity.
Article
The NEJM reports on a controlled clinical trial showing patients hospitalized with Covid-19 given hydroxychloroquine (HCQ) do not have a lower incidence of death compared to those receiving routine care.
Article
Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com.
Dr. John Cush
Tweet
Safety of nintedinib (NIN)in PSS-ILD - 576 PSS pts given NIN 150 mg bid or PBO x52wks. Dose lowered to 100 mg bid for AE. Diarrhea seen in 76% of NIN and 32% in PBO (d/c in 6.9% & 0.3%). Dose reduction in 48% & 12%. RCT discontinuation in 16% & 8.7% https://t.co/v5NxwlHu37
Dr. John Cush
Tweet
PI facts: did you know that JAK inhibitors(UPA, Bari, Tofa) have a warning against use w/ severe liver problems. They have not been studied in pts w/ Hepatitis B or C. UPA Bari & toga can be used in mild liver dz; Tofa only at 5 mg/d w/ moderate liver dz https://t.co/lnXrf12tjA
Dr. John Cush
Tweet
Listent to QD Clinics - A Podcast Weekly Compilation - Lessons from the clinic. Dr. Jack Cush discusses triage Rheumatology; Im Not Stupid; & Swollen but Not Painful
iTunes https://t.co/FHJv01Sb3a
SoundCloud https://t.co/fceBeXGu09
Dr. John Cush
Tweet
Empty out your medicine cabinets. Sat Oct 24th is DEA "TAKE BACK" day. Dispose of unused, unwanted, controlled drugs, narcotics, e-cigarettes. Theyll take your tablets, capsules, patches, pens, liquids (BUT NOT syringes, sharps, illegal drugs) Where? https://t.co/oDMYHl3mgI
Dr. John Cush
Tweet
Lilly has announced results of Phase 2 SERENITY trial showing the IL-23 inhibitor, mirikizumab, was more effective than PBO at week 12 (PRO and endoscopic outcomes) in moderate to severe active Crohn's disease. Efficacy continued out to week 52 https://t.co/n8Mdeonmas
Dr. John Cush
Tweet
SELECT CHOICE, H2H study of UPA vs ABA in TNF-IR RA pts; UPA had better DAS28-CRP & ABA had better Safety outcomes; Which would you use?
Dr. John Cush
Tweet
Not sure why this study was done...BUT... Tociiizumab was studied in 104 hand osteoarthritis and after 12 weeks, TCZ was equivalent to Placebo in achieving100mm VAS pain reduction (-9.9 vs -7.9), but TCZ had numerically more adverse events https://t.co/NYujNQbjvm
Angus Worthing MD
Tweet
@MattieRheumMD @News_CRA @statnews People are being crushed by co-pays- rheumatology patients' co-pays doubled to $1000 last year - and medical staff are wasting much time on paperwork. Plus, the @Aetna @CVSHealth merger caused prior auth meltdown in many. (Intentional?) Rebate system must go! ASK STAKEHOLDERS.
